NCT03362060: PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

NCT03362060
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: HLA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: 
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must be HLA-A2+
Exclusions: Known active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03362060

Comments are closed.

Up ↑